| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Meridian Bioscience (NASDAQ:VIVO) reported its Q3 earnings results on Friday, August 5, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
Meridian Bioscience reported in-line EPS of $0.16 versus an estimate of $0.16.
Revenue was up $4.26 million from the same period last year.
Last quarter the company beat on EPS by $0.19 which was followed by a 1.5% drop in the share price the next day.
Here's a look at Meridian Bioscience's past performance:
| Quarter | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
|---|---|---|---|---|
| EPS Estimate | 0.47 | 0.25 | 0.20 | 0.31 |
| EPS Actual | 0.66 | 0.35 | 0.23 | 0.22 |
| Revenue Estimate | 99.54M | 70.29M | 68.40M | 77.22M |
| Revenue Actual | 111.23M | 88.34M | 76.20M | 63.51M |
To track all earnings releases for Meridian Bioscience visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: VIVO
